[1] Robinson JW,Martin RM,Tsavachidis S,et al.Transcriptome-wide Mendelian randomization study prioritising novel tissue- dependent genes for glioma susceptibility[J].Sci Rep,2021,11(1):2329. [2] Sin HW,Nejad R,Zhang W,et al.Tissue 2-hydroxyglutarate as a biomarker for Isocitrate dehydrogenase mutations in gliomas[J].Clinical Cancer Research,2019,Jun,1,25(11):3366~3373. [3] Zuo B,Chen Y,Luo L,et al.Correlation between MGMT gene promoter methylation status and prognosis in patients with malig- nant glioma[J].Chinese Journal of Cancer Prevention and Treatment,2019,26(1):30~36. [4] Qu F,Wang P,Zhang K,et al.Manipulation of Mitophagy by “All- in- One”nanosensitizer augments sonodynamic glioma therapy[J].Autophagy,2020,16(8):1413~1435. [5] Shao N,Mao J,Xue L,et al.Carnosic acid potentiates the anti-cancer effect of temozolomide by inducing apoptosis and autophagy in glioma[J].Journal of Neuro-Oncology,2019,141(2):277~288. [6] Woolf EC,Rossi AP,Silvanichols HB,et al.Abstract 1125 A:β-hydroxybutyrate inhibits histone deacetylase activity and radiosensitizes malignant glioma cells[J].Cancer Research,2017,77(13):1125. [7] Dhakal A,Pokharel S,Wang K,et al.Abstract 5709:Variation in Merlin expression and its prognostic significance in malig- nant pleural mesothelioma[J].Cancer Research,2017,77(13 Sup- plement):5709. [8] 张晓星,李跃华.磁共振技术在脑胶质瘤术前分级中的应用进展[J].中国医学计算机成像杂志,2019,25(3):326~331. [9] Shen NX,Zhang JX,Gan TJ,et al.The 2021 WHO Classifification of Tumors of the Central Nerv-ous System:a summary[J].Fang She Xue Shi jian,2021,36(7):818~831. [10] Robin AM,Leel,Kalknis SN.Reoperation for recurrent glioblastoma multiforme[J].Neurosurg Clin N Am,2017,28(3):407~428. [11] 蒋辰,牛朝诗,凌士营,等.锥体束受侵犯程度与岛叶胶质瘤患者术后疗效的关系[J].中华神经外科杂志,2020,36(3):238~242. [12] Otani Y,Ichikawa T,Kurozumi K,et al.Dynamic reorganization of microtubule and glioma invasion[J].Acta Medica Okayama,2019,73(4):285~297. [13] 刘瀛,耿荣鑫,吴明洪,等.人脑胶质瘤组织BIRC2表达变化及临床意义[J].中国临床神经外科杂志,2021,26(5):333~335. [14] 顾润环,朱尔春.替莫唑胺联合放疗治疗恶性脑胶质瘤患者的临床研究[J].中国临床药理学杂志,2020,36(14):1202~1204,1227. [15] Anjali Arora,Kumaravel Somasundaram.Glioblastoma vs temozolomide:can the red queen race be won[J].Cancer Biology & Therapy,2019,0(8):1~8. [16] Himes BT,Zhang L,Daniels DJ,et al.Treatment strategies in diffuse midline gliomas with the H3K27M mutation:the role of convectionenhanced delivery in overcoming anatomic challenges[J].Front On-col,2019,8(9):31. [17] Butler M,Pongor L,Su YT,et al.MGMT status as a clinical biomarker in glioblastoma[J].Trends Cancer,2020,6(5):380~391. [18] Zhang DX,Qu YM,Zhang MS,et al.Influencing factors of progression-free survival in patients with WHO grade Ⅱ glioma[J].Chinese Journal of Neurosurgery,2019,35(5):469~473. [19] 刘宝辉,孙前,袁凡恩,等.高级别胶质瘤的治疗进展[J].中国临床神经外科杂志,2021,26(5):380~384. [20] 张庆浩,段文超,刘献志,等.无症状WHOⅡ级脑胶质瘤的疾病特征和术后生存分析[J].中华神经外科杂志,2020,8(4):405~406. [21] He K,Chi C,Li D,et al.Resection and survival data from a clinical trial of glioblastoma multiforme-specific IRDye 800-BBN fluorescence-guided surgery[J].Bioeng Transl Med,2021,6(1):e10182. [22] Wang MH,Feng Z.Value of conventional MRI texture analysis of peritumoral edema to distinguish glioblastoma and single metastases[J].Chinese Journal of Radiology,2018,52 (10):756~760. [23] Zhang YX.The correlation between corticospinal tract injury and motor function after stroke and the value analysis of magnetic resonance diffusion tensor imaging[J].Contemporary Med,2019,29(6):263~266. |